ReviewClinical transplantation and research2025
Laboratory approaches in desensitization for ABO-incompatible transplantation.
Review in Clinical transplantation and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Apheresis-Based Desensitization to Reduce Antibody Titer in ABO-Incompatible Kidney Transplantation: A Systematic Review and Meta-Analysis.Journal of transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ABO-incompatible transplantation, once considered contraindicated due to the risk of hyperacute rejection, has become a viable option owing to advances in immunosuppression and desensitization methods. Accurate measurement and effective reduction of anti-ABO isoagglutinin titers are essential for the success of ABO-incompatible transplantation. This review summarizes the principles of hemagglutination and the measurement of isoagglutinin titers, highlighting variables that influence agglutination sensitivity. The clinical significance of isoagglutinin rebound and its association with rejection risk are also discussed, along with ongoing efforts toward laboratory standardization. Antibody-mediated rejection (AMR) is strongly linked to high pretransplant isoagglutinin titers (≥1:32). Posttransplant isoagglutinin rebound-an important risk factor for AMR-requires careful monitoring in liver and kidney transplant recipients with high initial titers. Desensitization strategies include rituximab, plasmapheresis, intravenous immunoglobulin, bortezomib, and emerging agents such as tocilizumab and imlifidase. This review aims to enhance understanding of the immunological and laboratory aspects of ABO-incompatible transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.